

## Kerry Leifer General – 5/27/2021

### Agenda

#### CITAB Hiring/Staffing

- Status of Inert Team Leader hiring –Interviews completed 5/20, selection?
- Additional hire(s)
- Student Contractor status?
- NOWCC—per recommendation, NOWCC has extend offer to identified selected candidate. (NOWCC process to follow, including PSB)

#### Acute Toxicity

- Inpyrfluxam Acute Tox and CDPR/Valent issue (see pg 3-4 below)
- Process improvements for review assignments and scheduling –Timeline for reviews from date of receipt in CITAB (both PC and AT) discussed with subgroup of PMWG.
- Development of Acute Tox Priority Spreadsheet for RD

#### Inert Ingredients

- Propylene glycol and Ray McAllister/CLA et al proposal. Phase 1 letter issued 5/3. Phase 2 awaiting AD piece—email to E. Kraft and Anita.
- PFAS

## **Ex. 5 Deliberative Process (DP)**

- Commodity Inert Ingredients. Requests for further additions.
- Fragrance tolerance exemption petitions—Pat Quinn inquiries—team has developed action plan—response provided to Julie Timberman/Clorox
- Inert Team has developed detailed spreadsheet of all pending inert actions with eye to efficiencies in assignments/roles
- Bullets of steps being taken to address inert petition backlog has been drafted
- Inert Ingredient Branch Box – customer expectations vs resources—adding auto response language
- Microbial inert ingredients and role of BPPD

#### Product Chemistry

- Self-Certification—still awaiting OGC response to PR 98-1 certification statement—Allison Payne emailed 2/4
- ACB PC reviewer process continues - assignments made in conjunction with June prioritization

- SWAT TEAM – 2 FHB reviewers, one HB reviewer (started week of 3/8), one IVB2 (NOWCC reviewer)
- PFAS—review of Clarke products. First batches of reviews completed. Additional actions now in queue—two Clarke actions to be completed 6/7.
- RAB8—kickoff meeting held 5/25—initial assignments provided to RAB 5/26. Follow up meeting to be held week of 5/31 or 6/7.

#### Other CITAB issues/activities

- Midyears and awards completed.
- PFAS—Results of substructure search for PFAS in active ingredients
- CITAB Office hours—to be rescheduled for 5/20
- Additional funding for contractor—completed. Quarterly briefing with RD IO to be scheduled
- CSF Images and Documentum/ITRMD
- CITAB staff questions/concerns regarding USA Access Credential and move prep—property pass issue.

Dear Ms. Giles-Parker and Ms. Garvie,

Valent U.S.A. LLC has two new product registrations pending with CDPR that were submitted November 2019: S-2399 2.84 SC Fungicide, EPA Reg. No. 59639-230 (Excalia® Fungicide), and S-2399 3.2 FS Fungicide, EPA Reg. No. 59639-231 (Zeltera® Fungicide).

The data packages for these formulations have been reviewed by the US EPA and registration was granted in August 2020. As part of the data packages, a complete set of acute toxicity studies was submitted in support of the registration. The results are described in the tables below.

Following submission of these same data packages to the CDPR for review and approval, CDPR disagreed with the conclusion of the US EPA's interpretation of the acute oral toxicity study (MRID 49706201) for S-2399 2.84 SC Fungicide, 59639-230 (Excalia® Fungicide). The CDPR reviewer determined the LD<sub>50</sub> was 175 mg/kg, Category II for acute oral toxicity.

The acute oral toxicity study was conducted using the Up-Down technique in conjunction with the Acute Oral Toxicity (Guideline 425) Statistical Program (Westat, version 1.0, May 2001), as recommended by the US EPA <sup>1</sup>. The conclusion of the study report, as reflected by the EPA's Data Evaluation Report (DER), is an LD<sub>50</sub> of 550 mg/kg. Study results are captured in the table below

CDPR's interpretation of the study results were more conservative and determined the rat oral LD<sub>50</sub> was 174 mg/kg, toxicity category II. The justification for this conclusion is as follows; "It is this HHA reviewer's contention that due to the paucity of the study results, a conservative interpretation is in order. **Simply the fact that 2 of the 3 animals died when dosed with 550 mg/kg would preclude establishing the LD50 value at 550 mg/kg.** In the probit analysis of dose-response data, the slope of the curve dictates the calculated LD50 value. In this instance the data are so minimal that such an assessment is not possible. **Therefore, it was concluded that the Category II hazard was appropriate for this product in the light of the submitted data."**

The discrepancy in conclusions by the US EPA (LD<sub>50</sub>=550 mg/kg, Category III) and the CDPR (LD<sub>50</sub>=174 mg/kg, Category II) presents a conflict and poses critical issues for Valent in terms of labeling and use patterns. The EPA approved the label for S-2399 2.84 SC Fungicide which currently complies with safety and precautionary statements consistent with Category III acute oral toxicity results. If CDPR's conclusion is finalized, Valent will have to amend the label at USEPA to reflect CDPR's recommendation. It is not practical nor feasible to have separate labels for California and the rest of the US. The alternative is to revert to testing techniques that use a large number of animals, which is unacceptable

and is in direct opposition to the EPA's recent proclamation to reduce animal testing by 30% by 2025 and completely by 2035<sup>2</sup>. Furthermore, the up-and-down method using the AOT425 Statistical Program is acceptable for the Series 870 Health Effects Test Guidelines for acute toxicity testing and by the Organisation for Economic Co-operation and Development member nations.

Therefore, Valent is seeking advice from the EPA to rectify the issues created by CDPR's interpretation of the acute oral toxicity study. We would like to ask several questions regarding the issue:

- • Has the EPA encountered similar examples where CDPR had different interpretations for acute toxicity studies? If so how did the Agency address these differences?
  
- • What are the Regulatory ramifications of having label precautionary statements consistent with toxicity category III for Federal labels while having more precautionary statements on California labels?
  
- • What options do we have as a company to address these discrepancies in scientific conclusions between Federal and State Agencies?